OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Recent Advances in Synergistic Antitumor Effects Exploited from the Inhibition of Ataxia Telangiectasia and RAD3-Related Protein Kinase (ATR)
Liwei Wang, Songwei Jiang, Yinghui Yuan, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2491-2491
Open Access | Times Cited: 9
Liwei Wang, Songwei Jiang, Yinghui Yuan, et al.
Molecules (2022) Vol. 27, Iss. 8, pp. 2491-2491
Open Access | Times Cited: 9
Showing 9 citing articles:
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 16
Viola Previtali, Greta Bagnolini, Andrea Ciamarone, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 14, pp. 11488-11521
Open Access | Times Cited: 16
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)
W. Cameron Black, Abbas Abdoli, Xiuli An, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2349-2368
Closed Access | Times Cited: 7
W. Cameron Black, Abbas Abdoli, Xiuli An, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2349-2368
Closed Access | Times Cited: 7
Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy
Kristina Viktorsson, Thorsten Rieckmann, Maximilian Fleischmann, et al.
Strahlentherapie und Onkologie (2023) Vol. 199, Iss. 12, pp. 1091-1109
Open Access | Times Cited: 12
Kristina Viktorsson, Thorsten Rieckmann, Maximilian Fleischmann, et al.
Strahlentherapie und Onkologie (2023) Vol. 199, Iss. 12, pp. 1091-1109
Open Access | Times Cited: 12
Targeting the DNA Damage Response Machinery for Lung Cancer Treatment
Katharigatta N. Venugopala
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1475-1475
Open Access | Times Cited: 17
Katharigatta N. Venugopala
Pharmaceuticals (2022) Vol. 15, Iss. 12, pp. 1475-1475
Open Access | Times Cited: 17
Progress of ATM inhibitors: opportunities and challenges
Shan Du, Qi Liang, Jianyou Shi
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116781-116781
Closed Access | Times Cited: 2
Shan Du, Qi Liang, Jianyou Shi
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116781-116781
Closed Access | Times Cited: 2
Progression of monoclonal gammopathy of undetermined significance to multiple myeloma is associated with enhanced translational quality control and overall loss of surface antigens
Sigrid Ravn Berg, Aida Dikic, Animesh Sharma, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Sigrid Ravn Berg, Aida Dikic, Animesh Sharma, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 2
Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, et al.
Therapeutic Advances in Hematology (2023) Vol. 14
Open Access | Times Cited: 2
Mutual ATRaction: Assessing Synergy of Berzosertib with Sacituzumab Govitecan
Stephanie Berg, Atish D. Choudhury
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3557-3559
Closed Access | Times Cited: 2
Stephanie Berg, Atish D. Choudhury
Clinical Cancer Research (2023) Vol. 29, Iss. 18, pp. 3557-3559
Closed Access | Times Cited: 2
Strahlentherapie und molekular zielgerichtete Therapie – alles gezielt?
Sören Schnellhardt, Markus Hecht
Deleted Journal (2024) Vol. 30, Iss. 10, pp. 938-944
Closed Access
Sören Schnellhardt, Markus Hecht
Deleted Journal (2024) Vol. 30, Iss. 10, pp. 938-944
Closed Access
